Search

Copyright of Progress in Modern Biomedicine is the property of Publishing House of Progress in Modern Biomedicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Progress in Modern Biomedicine is the property of Publishing House of Progress in Modern Biomedicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Progress in Modern Biomedicine is the property of Publishing House of Progress in Modern Biomedicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

To investigate the effect of budesonide suspension on Toll like receptor 4 (TLR4) / myeloid differentiation factor 88 (MyD88) / nuclear factor κB in lung tissue of asthmatic mice. 40 cough variant asthma mice models were established by CO sensitizing mice with 4 % ovalbumin and 2 % Al (OH3 ). The model rats were intervened with low, medium and high doses (0.2, 1.0 and 2.0 g/kg) of budesonide suspension and montelukast sodium respectively, once a day for 14 days, and the bronchoalveolar tissues were collected at the time of intervention for 14 days The levels of leukocytes (WBC), eosinophils, IFN-γ, IL-1β and TNF-α in BALF of each group were compared, and the differences in the scores of epithelial hyperplasia, inflammatory cell infiltration and total pathological changes, as well as the expression of TLR4, MyD88 and p65 proteins in lung tissue of each group were analyzed. Budesonide suspension can significantly reduce the number of leukocytes and eosinophils in BALF of asthmatic model mice, and can also improve the airway and bronchial epithelial hyperplasia and inflammatory cell infiltration in lung tissue of mice, and the expression levels of TLR4, MyD88 and p65 protein in lung tissue of mice decreased significantly after intervention. Budesonide suspension can improve the asthma model mice The mechanism of action may be related to the regulation of TLR4, MyD88, p65 protein expression, and then affect the process of inflammation and immune response. [ABSTRACT FROM AUTHOR]

Objective: To investigate the efficacy of triptorelin combined with low-dose growth hormone in the treatment of girls with central precocious puberty (CPP) and its effect on bone age. Methods: A total of 200 girls with CPP, who were admitted to People's Hospital of Shaanxi Province from January 2017 to January 2020, were chosen as research subjects and were randomly divided into control group (n=100) and study group (n=100).The control group was given conventional treatment, and the study group was given triptorelin combined with low-dose growth hormone therapy. The clinical efficacy of, serum sex hormone levels before and after treatment, changes in uterine volume, ovarian volume, and changes in growth and development indicators of the two groups of patients were observed. Results: After treatment, the total effective rate (98 %) in the study group was significantly higher than that (80 %) in the control group (P<0.05). The levels of FSH, LH, E2, uterine volume, and ovarian volume of the two groups were reduced, and bone age, height, and PAH were significantly increased. The above indicators of the study group were significantly better than those of the control group (P<0.05). Conclusion: Triptorelin combined with low-dose growth hormone has a significant effect in the treatment of girls with CPP. It can improve the serum sex hormone levels, uterine volume, and ovarian volume of the girls with CPP . It has positive significance for growth and development indicators and is worthy of clinical promotion and application. [ABSTRACT FROM AUTHOR]

Objective: To investigate the effect of remifentanil on the cognitive function and cerebral oxygen metabolism in patients with intracranial aneurysms after acute hypervolemic hemodilution（AHH）. Methods: A total of 92 patients, who underwent intracranial aneurysm clipping in Suining Central Hospital from May 2015 to December 2016, were selected and were randomly divided into study group（n=46） and control group（n=46）. The study group was treated with remifentanil, and the control group was treated with nitroglycerin. Mean arterial pressure（MAP） and heart rate（HR） of the patients in the two groups before AHH（T0）, after AHH（T1）, before lowering blood pressure（T2）, 30 min after lowering blood pressure（T3）, 5 min after aneurysm clipping（T4） were recorded. The arterial and venous blood oxygen saturation（SAO2, SjvO2）, arterial oxygen partial pressure（PAO2）, and arterial oxygen partial pressure（PjvO2）were counted at T2-T4 time points. The arterial oxygen content（CAO2）, internal jugular vein oxygen content（CjvO2）, arterial internal jugular bulb oxygen deficit（Da-jvO2）, arterial bulb lactate difference（VADL） and brain oxygen uptake rate（CERO2） were calculated.The cognitive functions of two groups were evaluated by the Mini Mental State Scale（MMSE） before operation, 3 d and 7 d after operation. Results: Compared with the T2 time point, the MAP was decreased significantly in the two groups at T3 and T4 time points（P<0.05）. The HR in the control group was increased significantly, but the HR in the study group was decreased significantly（P<0.05）. The SaO2 of the two groups was 100%. At T3 and T4 time points, SjvO2 and CjvO2 in the study group were significantly higher than those at T2 time point,which was higher than those in the control group, and the differences were statistically significant（P<0.05）; the Da-jvO2 and CERO2 were significantly lower than at T2 time point, which were lower than those in the control group,and the differences were statistically significant（P<0.05）. There were no significant differences in the PaO2, CaO2, PjvO2, VADL between the two groups（P>0.05）.There were no significant differences in MMSE scores between the two groups before operation, 3 d and 7 d after operation（P>0.05）; the MMSE scores of the two groups before operation and 7 d after operation were higher than those of the two groups 3 d after operation（P<0.05）. Conclusion: Remifentanil in the acute hypervolemic hemodilution with intracranial aneurysm clipping can effectively maintain the stability of hemodynamics of patients, at the same time,the rate of cerebral oxygen metabolism can be effectively controlled. Compared with nitroglycerin, remifentanil is superior in acute hypervolemic hemodilution, but there is no obvious improvement in cognitive function. [ABSTRACT FROM AUTHOR]

Objective: To investigate the correlation between carotid artery intima media thickness (IMT) and vascular endothelial function and vascular adhesion factor-1 (VCAM-1)in elderly patients with metabolic syndrome (MS). Methods: Selected 50 cases of patients with MS in our hospital from October 2014 to January 2013 were divided into the elderly group (n=25)and young and middle-aged group (n=25), and were divided into normal group and the thickening group according to the IMT. Compare the clinical data of the elderly group and the young and middle-aged group, detected the level of endothelin-1(ET-1)in all patients by the radioimmunoassay, detected the level of nitric oxide(NO)by spectrophotometer with indirect colorimetric method, detected the level of VCAM-1 by ELISA method, Detected the IMT by ultrasonic diagnostic apparatus. Comparison and correlation analysis between groups on the above indicators. Results: There was no significant difference in the clinical data between elderly MS group and young and middle aged MS group (P>0.05); The levels of NO in the MS patients with IMT thickening group were lower than those in the IMT normal group, while the levels of ET-1 and VCAM-1 were higher than those in the IMT normal group,the differences were statistically significant (P<0.05); Comparison of IMT thickening group, the level of NO in the elderly MS group was lower than that in young and middle aged MS group, the level of VCAM-1 was higher than that in the young and middle aged MS group, and the differences were statistically significant (P<0.05); IMT was negatively correlated with the level of NO in the elderly MS group and young and middle aged MS group (r=-0.415,-0.411; P=0.043, 0.049), and were positively correlated with the levels of ET-1 and VCAM-1 (r=0.585, 0.576; P=0.030, 0.036; r=0.547, 0.552; P=0.033, 0.031). Conclusion: Multiple factors, such as vascular endothelial dysfunction and atherosclerosis,promote the occurrence and development of IMT thickening in MS patients. [ABSTRACT FROM AUTHOR]

Copyright of Progress in Modern Biomedicine is the property of Publishing House of Progress in Modern Biomedicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Progress in Modern Biomedicine is the property of Publishing House of Progress in Modern Biomedicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Progress in Modern Biomedicine is the property of Publishing House of Progress in Modern Biomedicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Progress in Modern Biomedicine is the property of Publishing House of Progress in Modern Biomedicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Progress in Modern Biomedicine is the property of Publishing House of Progress in Modern Biomedicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Progress in Modern Biomedicine is the property of Publishing House of Progress in Modern Biomedicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)